If KDEL receptors are activated by XBP1 in cancer cells, the inhibition of the IRE1 pathway would predictably prevent KDEL receptor upregulation and deny tumor cells the benefits afforded them by increased KDEL receptors. The gene discussed is ERN1; the disease is neoplasm.